Drug Trial Radar · NCT06868485
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 18, 2025
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Wayshine Biopharm, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene.
Conditions
- Non Small Cell Lung Cancer
Interventions
WSD0922-FU Tablets, Dose level ADrug
Oral, 21 days in each cycle
WSD0922-FU Tablets, Dose level BDrug
Oral, 21 days in each cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: every 8 weeks, up to 1 year
Locations
16 sites in 3 countries. Site status is shown where the registry gives one.
Cleveland Clinic Weston Hospital
Weston, Florida · Recruiting
Hackensack Meridian Health-Southern Ocean Medical Center
Manahawkin, New Jersey · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
TxO Central/South, Texas Oncology -Central/South Texas
Austin, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Wuhan Union Hospital
Wuhan, Hubei, China · Recruiting
Shanghai East hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Centre Hospitalier Universitaire (CHU) de Rennes - Hopital de Pontchaillou
Rennes, Ille-et-Vilaine, France · Recruiting
Centre Hospitalier Universitaire CHU De Limoges
Limoges, New Aquitaine, France · Recruiting
CHU Bordeaux - Centre Francois Magendie
Pessac, New Aquitaine, France · Recruiting
Centre Francois Baclesse
Caen, Normandy, France · Recruiting
CHU Toulon - Hopital Sainte Musse
Toulon, Var, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.